Combined use of oxytocin and human chorionic gonadotropin in intractable pain patients

Following doses of oxytocin (OT) and human chorionic gonadotropin (HCG), 7 of 9 patients reported a 30% to 40% reduction in opioid use and baseline pain, in results reported today at the 30th Annual Meeting of the American Academy of Pain Medicine. In addition, the patients reported less intense pain flares, which are sudden exacerbations of pain that occur against a background of persistent pain, and longer periods between flares.

Study author Forest Tennant, MD, said side effects were remarkably few, probably because the hormones are natural, bio-identical compounds. Dr. Tennant is an internist and addictionologist who specializes in research and treatment of intractable pain at the Veract Intractable Pain Clinics he founded in West Covina, Calif.

"The benefit that these patients mostly talk about is somewhat subjective but relates to what patients routinely call a 'feeling of well-being,' 'more alive,' or [increasing] 'will to live," Dr. Tennant said. "They also believe the combination is one they want to continue."

Sometimes referred to as the "bonding hormone," OT exerts powerful action in the neuroanatomy of intimacy and also acts as a neurotransmitter in the brain. HCG supports the development of the fetus during pregnancy among other roles.

Both hormones surge during and after childbirth, and pregnant women have frequently exhibited reduced pain and need for opioids. Dr. Tennant has conducted previous small open-label studies that confirmed a similar effect for both hormones when administered separately in patients who suffer from intractable pain. However, no one had tested the effect of administering both hormones simultaneously until now.

The study, which was cleared by the facility's Institutional Review Board, included 9 patients with intractable pain who were being maintained on 1 or more long- and short-acting opioids. Daily dosages were administered beneath the tongue of HCG ranging from 250 to 500 units and OT in 10 units taken 2 to 4 times. Patients were evaluated for pain relief, side effects, energy, mental function and opioid dose reduction at 2 to 3 months.

One patient stopped the regimen entirely, saying it had no effect. Another patient stopped taking OT because it made her weepy and despondent but continued taking HCG.

All other patients reported a 30% to 40% reduction in opioid use, reduction in baseline pain, flare intensity, or increase in time between flares. Reports of energy, improved mental functions, mood and libido were variable.

Dr. Tennant said though it is premature to justify this type of hormonal therapy in any but patients who are non-responsive to standard treatments, these preliminary results are worth pursuing as an alternative to more symptomatic conventional treatments for intractable pain. Next steps for increasing the clinical relevance of results would be additional open-label trials by multiple observers, he said. He further expects biomarkers of neuroinflammation and glial cell metabolic disturbance to be useful for monitoring treatment success and, to a great extent, influencing treatment selection.

Poster 187 -- Combined Use of Oxytocin and Human Chorionic Gonadotropin in Intractable Pain Patients